NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
Pembrolizumab in HER2-Positive Gastric Cancer
The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and...
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
